{"id":"W4406238848","doi":"10.1016/j.ejca.2024.115146","title":"Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Regeneron Pharmaceuticals","keywords":"Cervical cancer; Medicine; Phase (matter); Oncology; Internal medicine; Cancer; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001971065,0.0008811363,0.002008036,0.0002247288,0.0002454163,0.0009820458,0.0005891187,0.0007338375,0.003425729],"category_scores_gemma":[0.001867143,0.0002465761,0.001794118,0.0003555674,0.0004401082,0.0007615885,0.0004305167,0.002743032,0.0005552095],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007944824,"about_ca_system_score_gemma":0.0009323135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009294288,"about_ca_topic_score_gemma":0.004025985,"domain_scores_codex":[0.9994226,0.0003482443,0.00001674103,0.00007728242,0.00003641588,0.00009873135],"domain_scores_gemma":[0.9993184,0.0002183632,0.000136293,0.00008551208,0.00003366434,0.0002077428],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.73232,0.002512821,0.01245678,0.002463702,0.006150682,0.0002065338,0.0002240809,0.009297914,0.007348704,0.001330156,0.02091972,0.2047689],"study_design_scores_gemma":[0.7032435,0.1626484,0.07738958,0.0007191398,0.01044931,0.0009391739,0.0003452867,0.01092304,0.0035165,0.004757056,0.02493952,0.000129485],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9648623,0.01993785,0.0007617079,0.00170757,0.0003289655,0.0006211912,0.00470488,0.0001876053,0.006887945],"genre_scores_gemma":[0.9848321,0.003814404,0.0009527107,0.001078253,0.0001695457,0.0006205558,0.004977147,0.00005744945,0.003497885],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003425729,"threshold_uncertainty_score":0.01146019,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05234366053193121,"score_gpt":0.3867220006093425,"score_spread":0.3343783400774113,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}